EUCTR2021-002818-13-DE
Active, not recruiting
Phase 1
A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5Ra) in Adult Patients with Chronic Prurigo. - BICPIC
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Charité-Universitätsmedizin Berlin
- Enrollment
- 48
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis: chronic prurigo (defined as ongoing disease)
- •1\.Patient is informed about study procedures and medications and has given written informed consent before any assessment.
- •2\.Patient is able to communicate with the investigator, understands and complies with the requirements of the study.
- •3\.Clinical diagnosis of CPG for at least 6 months with:
- •Severe pruritus with WI\-NRS rating \= 6 (Mean of the worst daily intensity over the previous 3 days at Screening and over the previous week at baseline \[minimum of at least 5 days during the week preceding the baseline visit]).
- •Pruriginous nodular, papular, plaque and/or umbilicated lesions on upper limbs, trunk, and/or lower limbs
- •At least 20 CPG lesions on the entire body with a bilateral distribution
- •4\.Willing and able to complete a daily symptom Diary for the duration of the study and adhere to the study visit schedules.
- •5\.Women of childbearing potential (WOCBP) must agree to use a highly effective method of birth control
- •6\.Negative COVID\-19 test
Exclusion Criteria
- •1\.Chronic pruritus resulting from another active condition other than CPG
- •2\.Unilateral lesions of prurigo (e.g., only one arm affected)
- •3\.Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half\-lives of enrollment, whichever is longer.
- •4\.Patients who previously received benralizumab
- •5\.Patients with hypersensitivity to any of the excipients of the IMP or history of anaphylaxis to any biologic therapy or vaccine.
- •6\.Any disorder that is not stable in the opinion of the Investigator and could: (a) Affect the safety of the participant throughout the study, (b) Influence the findings of the studies or their interpretations, (c) Impede the participant’s ability to complete the entire duration of study.
- •7\.Inability to comply with study and follow\-up procedures.
- •8\.Current malignancy, or history of malignancy within the last 5 years
- •9\.Current active liver disease
- •10\.A history of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentAlcoholic hepatitisMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2020-004534-38-DEDURECT Corporation300
Active, not recruiting
Not Applicable
A Clinical Trial Investigating OSI-906 in Patients with Adrenocortical CarcinomaAdrenocortical CarcinomaMedDRA version: 14.1Level: PTClassification code 10001388Term: Adrenocortical carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2009-012820-97-DEAstellas Pharma Global Development, Inc.135
Recruiting
Phase 3
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast CancerBreast cancerBreast carcinoma10006291NL-OMON51870Merck Sharp & Dohme (MSD)24
Active, not recruiting
Not Applicable
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseSecondary hyperparathyroidism in subjects with chronic kidney diseaseMedDRA version: 17.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 17.0Level: LLTClassification code 10020706Term: Hyperparathyroidism NOSSystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Diseases [C] - Symptoms and general pathology [C23]EUCTR2012-002805-23-ATKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)500
Active, not recruiting
Phase 1
A phase 3 randomised, double-blind, placebo-controlled efficacy and safety study funded by Furiex Pharmaceuticals. The purpose of this study is to find out if a new investigational drug called JNJ-27018966 is safe and effective as a treatment for diarrhea-predominant Irritable Bowel Syndrome (IBS-d).Diarrhea-predominant irritable bowel syndromeMedDRA version: 20.1 Level: LLT Classification code 10060845 Term: Diarrhea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1 Level: PT Classification code 10023003 Term: Irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]EUCTR2012-001600-38-GBFuriex Pharmaceuticals1,282